Mondego Bio
Company Details
About: Mondego Bio is developing best-in-class Protein tyrosine phosphatase non-receptor type 2 (PTPN2) inhibitors, providing a potential immuno-oncological therapy with an improved safety and tolerability profile.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Mondego Bio | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.